Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Total Non-Current Liabilities (2016 - 2022)

Historic Total Non-Current Liabilities for vTv Therapeutics (VTVT) over the last 9 years, with Q1 2022 value amounting to $13.1 million.

  • vTv Therapeutics' Total Non-Current Liabilities rose 2718.74% to $13.1 million in Q1 2022 from the same period last year, while for Mar 2022 it was $13.1 million, marking a year-over-year increase of 2718.74%. This contributed to the annual value of $9.0 million for FY2021, which is 1786.95% down from last year.
  • Latest data reveals that vTv Therapeutics reported Total Non-Current Liabilities of $13.1 million as of Q1 2022, which was up 2718.74% from $9.0 million recorded in Q4 2021.
  • vTv Therapeutics' Total Non-Current Liabilities' 5-year high stood at $43.2 million during Q2 2018, with a 5-year trough of $8.3 million in Q3 2021.
  • In the last 5 years, vTv Therapeutics' Total Non-Current Liabilities had a median value of $16.8 million in 2020 and averaged $19.9 million.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first soared by 4495.31% in 2018, then plummeted by 4982.16% in 2019.
  • vTv Therapeutics' Total Non-Current Liabilities (Quarter) stood at $28.7 million in 2018, then crashed by 37.75% to $17.8 million in 2019, then tumbled by 38.66% to $10.9 million in 2020, then fell by 17.87% to $9.0 million in 2021, then soared by 46.17% to $13.1 million in 2022.
  • Its Total Non-Current Liabilities stands at $13.1 million for Q1 2022, versus $9.0 million for Q4 2021 and $8.3 million for Q3 2021.